Impact of polatuzumab vedotin on the pharmacodynamics of mosunetuzumab by assessing the CD4+ and CD8+ change from baseline for A, CD69, B, HLA-DR and C, margination.
BLOOD
Note: T-cell markers (percentages of CD69+ and PD1+ in CD4 and CD8 T cells) and cell counts of CD4 and CD8, in peripheral blood, were measured at baseline, 30 minutes after polatuzumab vedotin dosing and 2 hours after mosunetuzumab at multiple time points. Blood samples from patients treated with 1/2/60/30 mg of mosun-pola, were evaluated for T cell activation and margination, at C1D1-PRE. (
